articles This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Article 3 days ago - 21 mins read 2021 First-in-Class Large Molecule Drug Approvals (Pt. III) This deep dive into 2021’s first-in-class large molecule drug approvals is the third in a series of focus articles on 2021’s novel large molecule drugs. See part one here, and part two here. For each of the 11 first-in-class large molecule drug approvals of 2021 (excluding vaccines), we’ll explore in more detail: how they work… Article 4 days ago - 6 mins read May 2022 Molecules of the Month Runners Up Readers have been asking for more molecules, so this month, we’re starting a new feature that will highlight a few of the molecules we liked that didn’t make it into Molecules of the Month. There were six runners-up this month, including an orally bioavailable, brain penetrant inhibitor of PAAN/MIF, and a STING agonist discovered using… Article 1 week ago - 4 mins read Shaken by An Unexpected Patient Connection with Julien Lefranc We asked one of our reviewers, Julien Lefranc, about what inspires and excites him about drug discovery. Here, he tells us about an unexpected, moving connection with a cancer patient, and what drives him to work every day. About Julien Julien is a Principal Scientist at Merck KGaA in Darmstadt and is… Article 1 week ago - 1 min read Molecules of the Month – May 2022 A fat-tissue-targeting clinical candidate, a first-in-class Ph. III molecule that inhibits its target by covalently modifying the target’s substrate, and a fourth-generation glucokinase activator are some examples in Drug Hunter’s May 2022 edition of Molecules of the Month. In this month’s slide deck, you’ll find a molecule that had mitigated QTc prolongation over a prior… Article 2 weeks ago - 2 mins read Drug Hunter In-Person Events Our first South San Francisco Drug Hunter event was so much fun, we’ve decided to host in-person events all over the world. The next few events will be networking mixers, but stay tuned for scientific symposia and conferences! Sign up here to get invites to future in-person events around the world, including in Boston, Basel,… Article 3 weeks ago - 12 mins read Acceleron’s TGF-beta Ligand Trap, Trillium’s SIRP-alpha Fusion Proteins, and Eight Other Large Molecules Acquired in 2021 Our team conducted a review of all of the biotech mergers and acquisitions of 2021 and distilled it down to the acquisitions of drug discovery-focused biotechs here. There were 10 acquisitions of companies with large molecule drug assets in 2021. Here is a more in-depth look into all of the lead large molecules acquired in 2021,… Pages: 123456789101112Load More
